NEWS
Gemini Administration Induced Statistically Significant, Dose Dependent Changes in Key Biomarkers of Activity
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
Revelation Biosciences announced that its Phase 1 clinical study of Gemini met its primary safety endpoint and showed statistically significant biomarker activity. The study, conducted with 40 healthy volunteers aged 18-55 in Australia, found that Gemini was safe and well-tolerated at pharmacologically active doses. Significant dose-dependent changes in key biomarkers, such as interleukin-1RA, neutrophil gelatinase lipocalin, C-reactive protein, and IL-6, were observed, indicating the drug's immunostimulatory effects. The Phase 1 results support further development across multiple indications, including acute kidney injury prevention and postoperative infection prevention. The maximum tolerated dose identified will guide the upcoming Phase 1b study in chronic kidney disease patients planned for late 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1075Followers
68Following
7381Visitors
Follow